Compare CTRI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | AAPG |
|---|---|---|
| Founded | 1909 | 2009 |
| Country | United States | China |
| Employees | 9687 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2024 | N/A |
| Metric | CTRI | AAPG |
|---|---|---|
| Price | $30.60 | $24.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $29.85 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.5M | 1.7K |
| Earning Date | 02-25-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $2,982,781,000.00 | N/A |
| Revenue This Year | $13.82 | N/A |
| Revenue Next Year | $8.39 | $368.64 |
| P/E Ratio | $122.40 | ★ N/A |
| Revenue Growth | ★ 13.10 | N/A |
| 52 Week Low | $14.46 | $17.56 |
| 52 Week High | $32.38 | $48.45 |
| Indicator | CTRI | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 48.01 |
| Support Level | $19.76 | $23.12 |
| Resistance Level | $32.38 | $25.47 |
| Average True Range (ATR) | 1.11 | 0.77 |
| MACD | -0.11 | 0.20 |
| Stochastic Oscillator | 77.33 | 67.06 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.